Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase 3 registration clinical trial of Epanova, the company’s lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
The multi-center, placebo-controlled, randomized, double-blind, 12-week study will evaluate the efficacy and safety of three doses of Epanova in patients with fasting triglyceride (TG) levels of ?500 mg/dL. The trial is expected to enroll approximately 300 patients and will be conducted in centers throughout North America, Europe and India. The primary endpoint of the trial, known as EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs), is the percentage change in triglyceride level from baseline to week 12.
“An estimated five million people in the U.S., alone, have triglyceride levels greater than 500mg/dL, a serious lipid disorder that is rapidly growing in prevalence throughout the world,” said Jerry Wisler, President and Chief Executive Officer of Omthera. “This SPA marks an important milestone for Omthera, providing a clear regulatory pathway to approval for Epanova in this patient population. We look forward to commencing this Phase III trial in the coming months.”
In addition to the EVOLVE study, Omthera has initiated a pharmacokinetic trial for Epanova, known as ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic, Single-dose Evaluation), intended to demonstrate bioavailability advantages over currently available prescription Omega 3 products. Data from this study is expected in the first quarter of 2011.
“Cardiovascular disease continues to be the leading cause of death worldwide, and high triglycerides are an important contributing factor,” said John J. P. Kastelein, M.D., Ph.D., Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam and principal investigator for the EVOLVE study. “Epanova therefore has the potential to be an innovative therapy to help patients control their triglyceride levels.”
Date: November 22, 2010
Source: Omthera Pharmaceuticals, Inc.
